Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Section 3 of 6

Product information and disease description

361 evidence topics · 144 sources

Product description

Phase of product development

Summary: regulatory history and status
  • Current status: under FDA review. Apnimed submitted a New Drug Application (NDA) for Oxnimbi (AD109) through the section 505(b)(2) pathway in April 2026; the FDA accepted it for review in July 2026 and assigned a PDUFA goal date of February 28, 2027. The 10-Q states that the review cycle is targeted at 10 months from the April 2026 submission. No launch date has been stated.
  • Designations: Fast Track designation for the treatment of OSA in May 2022.
  • Proprietary name: Oxnimbi is a proposed name. The prospectus states that the FDA conditionally approved it in May 2025, reconfirmed it in June 2026, and that it is pending approval of the NDA; the third quarter 2026 release states that it remains subject to final FDA review and may change.
  • Combination product requirement: as a fixed-dose combination, the product generally requires the sponsor to demonstrate the contribution of each component to the claimed effect and the safety and efficacy of the combination as a whole.
  • FDA questions: at the pre-NDA meeting, the FDA gave feedback on the “clinical meaningfulness of certain endpoint results”, including the primary endpoint, and on the limitations of the patient-reported outcomes, and indicated that additional analyses and justification may be needed to show a clinically meaningful benefit. Apnimed states that it responded in the NDA. The third quarter 2026 Form 10-Q states that the FDA, in its acceptance letter and later communications, has raised questions regarding the adequacy of the NDA and has requested additional information, data, or analyses on the nonclinical, clinical, or CMC areas; its risk factors name the adequacy of stability data and the manufacturing process.
  • Development completed: 13 phase 1, 2, and 3 trials, including two registrational phase 3 trials (LunAIRo in the United States and SynAIRgy in the United States and Canada).
  • Earlier timing statements, now superseded: the May 2025 and July 2025 topline releases planned an NDA submission by early 2026; the March 2026 release expected submission in the second quarter of 2026; the April 2026 debt financing release expected it later that quarter; the May 2026 SynAIRgy publication release expected a PDUFA target action date in the first quarter of 2027, subject to FDA acceptance. The July 2026 acceptance, with a goal date of February 28, 2027, replaced these statements.
Launch

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Dosage forms and strengths
Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Atomoxetine label: pharmacokinetic parameters by CYP2D6 metabolizer type
ParameterOther CYP2D6 metabolizer typesCYP2D6 poor metabolizers
Accumulation“1.1-fold”“3.3-fold”
Absolute bioavailability“63%”“94%”
Median time to maximum concentration“1 hour”“2.5 hour”
Atomoxetine half-life“5.2 hours”“21.6 hours”
Atomoxetine apparent oral clearance“0.35 L/hr/kg”“0.03 L/hr/kg”
Primary metabolic pathways“CYP2D6”“Other CYP enzymes”
Oxybutynin label: R-oxybutynin and S-oxybutynin after a single 10 mg extended-release dose
ParameterR-oxybutyninS-oxybutynin
Cmax (ng/mL), mean (SD)“1.0 (0.6)”“1.8 (1.0)”
Tmax (h), mean (SD)“12.7 (5.4)”“11.8 (5.3)”
Half-life (h), mean (SD)“13.2 (6.2)”“12.4 (6.1)”
AUCinf (ng•h/mL), mean (SD)“21.3 (12.2)”“39.5 (21.2)”
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information for AD109

Not applicable.

SynAIRgy: treatment-emergent adverse events in the safety analysis set
Cardiovascular effects: heart rate and blood pressure, pooled phase 3 safety analysis set
MeasureAD109 (n = 653)Placebo (n = 646)P value
Heart rate (beats/min), mean change from baseline to week 26, evening before PSG, mean (SD)“2.0 (11.2)”“-0.7 (10.0)”Not reported
Heart rate (beats/min), mean change from baseline to week 26, morning after PSG, mean (SD)“3.4 (9.5)”“-0.7 (9.4)”Not reported
Systolic blood pressure (mm Hg), mean change from baseline to week 26, evening before PSG, mean (SD)“0.9 (12.0)”“-1.2 (12.3)”Not reported
Diastolic blood pressure (mm Hg), mean change from baseline to week 26, evening before PSG, mean (SD)“0.7 (8.4)”“-1.5 (7.8)”Not reported
Heart rate ≥100 beats/min on study, n (%)“48 (7.4)”“28 (4.3)”“0.021”
Systolic blood pressure ≥140 mm Hg on study, n (%)“175 (26.8)”“168 (26.0)”“0.760”
Diastolic blood pressure ≥90 mm Hg on study, n (%)“146 (22.4)”“131 (20.3)”“0.368”
Special populations
Phase 3 trial population: age, cardiovascular, urinary, ocular, and pregnancy criteria
Drug/Drug, drug/disease interactions
Effects of other drugs on AD109
Effects of AD109 on other drugs
Dosing and administration
Dosage
Administration
Access and distribution
Co-prescribed/Concomitant therapies
Effect of AD109 on quality measures
Product-specific effect on quality measures

No evidence found.

American Academy of Sleep Medicine adult obstructive sleep apnea quality measure set, 2022 update

“Two of the measures are currently included in the Merit-based Incentive Payment System (MIPS) program, which replaced the PQRS program, as a part of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For the purposes of this measure, evidence-based therapies include positive airway pressure, oral appliances (custom, titratable, Food and Drug Administration [FDA]–cleared appliances), positional therapies, upper airway surgeries, hypoglossal nerve stimulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Proportion of patients aged 18 years and older diagnosed with OSA that showed any improvement in their quality of life (QoL) from baseline within 1 year of starting treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The Task Force reviewed this measure and agreed that, although there is not yet convergence on exactly which HRQoL instrument should be used, this is an important outcome to measure and document, as it will speak to the effectiveness of the assessments and treatment captured in the process measures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The registry is approved by CMS as a Qualified Clinical Data Registry, for reporting quality measures as a part of the Quality Payment Program, a national quality reporting initiative that includes MIPS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Product comparison
Head-to-head and indirect comparisons of AD109 with other OSA treatments

No evidence found.

Place of product in therapy

Disease description

Definition and etiology
Obesity as a risk factor: share of adults with OSA who have obesity, AHI of 5 or more with 4% desaturation hypopnea rule (individual participant data meta-analysis with Apnimed authors)
Epidemiology
Incidence of Obstructive sleep apnea
Prevalence of Obstructive sleep apnea
US prevalence in 2024, AHI4 of 5 or more, adults aged 20 years and older (systematic review and obesity-adjusted projection by Clarivate and Apnimed authors)

“A literature-based systematic review was conducted to identify studies of OSA prevalence in adults using the AHI4 criteria (all apneas plus hypopneas associated with ≥4% oxygen desaturation).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“OSA was defined as having an AHI4 ≥ 5 events/hr.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 83.7 million adults (aged 20 years and older) were estimated to be living with OSA in the US in 2024, of whom 49,459,041 (59%) were males and 34,257,378 (41%) females.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This translates to 32.4% overall prevalence in the US among adults aged 20 years and older, with 39.1% among males and 26.0% in females, adjusting for obesity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The distribution of OSA severity was estimated to be 52% mild, 30% moderate, and 18% severe.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“I.S. and A.V.D. are employees of Clarivate Analytics. K.S.Y., J.C., and J.Y. are employees of Apnimed, Inc.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

US prevalence in 2007 to 2010, AHI of 5 or more and 15 or more with 4% desaturation hypopnea rule, adults aged 30 to 70 (Wisconsin Sleep Cohort extrapolated to NHANES body mass index distributions)

“A discernible reduction in the sum of thoracic plus abdomen respiratory inductance plethysmography amplitude associated with a 4% or more reduction in oxyhemoglobin saturation defined a hypopnea event.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The current prevalence estimates of moderate to severe sleep-disordered breathing (apnea-hypopnea index, measured as events/hour, ≥15) are 10% (95% confidence interval (CI): 7, 12) among 30–49-year-old men; 17% (95% CI: 15, 21) among 50–70-year-old men; 3% (95% CI: 2, 4) among 30–49-year-old women; and 9% (95% CI: 7, 11) among 50–70 year-old women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“These estimated prevalence rates represent substantial increases over the last 2 decades (relative increases of between 14% and 55% depending on the subgroup).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Summing over age × sex × BMI strata, we estimated the overall prevalence of mild to severe SDB (AHI ≥5) to be 26% (95% confidence interval: 24, 28) among person 30–70 years of age for the recent time period (2007–2010).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Similarly, the estimated overall prevalence of moderate to worse SDB (AHI ≥15) was 10% (95% confidence interval: 8, 11).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We also estimate that 14% of men and 5% of women have an AHI ≥5 plus symptoms of daytime sleepiness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Global prevalence, AHI of 5 or more and 15 or more with AASM 2012 criteria, adults aged 30 to 69 (ResMed-funded)
US prevalence, AHI of 5 or more and 15 or more with AASM 2012 criteria, adults aged 30 to 69 (country table of the global estimate)
US prevalence projected from 2020 to 2050, AHI of 5 or more, adults aged 30 to 69, hypopnea scoring rule not stated (ResMed-funded simulation model)
Natural history, survival, and mortality
All-cause mortality: Sleep Heart Health Study, apneas and hypopneas with 4% desaturation

“We prospectively examined whether sleep-disordered breathing was associated with an increased risk of death from any cause in 6,441 men and women participating in the Sleep Heart Health Study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The apnea–hypopnea index (AHI) was defined as the number of apneas and hypopneas, each associated with a 4% or greater decrease in oxygen saturation, per hour of sleep.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The average follow-up period for the cohort was 8.2 y during which 1,047 participants (587 men and 460 women) died. Compared to those without sleep-disordered breathing (AHI: <5 events/h), the fully adjusted hazard ratios for all-cause mortality in those with mild (AHI: 5.0–14.9 events/h), moderate (AHI: 15.0–29.9 events/h), and severe (AHI: ≥30.0 events/h) sleep-disordered breathing were 0.93 (95% CI: 0.80–1.08), 1.17 (95% CI: 0.97–1.42), and 1.46 (95% CI: 1.14–1.86), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Stratified analyses by sex and age showed that the increased risk of death associated with severe sleep-disordered breathing was statistically significant in men aged 40–70 y (hazard ratio: 2.09; 95% CI: 1.31–3.33). Measures of sleep-related intermittent hypoxemia, but not sleep fragmentation, were independently associated with all-cause mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Pathophysiology
Pharyngeal dilator muscle control: hypoglossal motor nucleus mechanisms targeted by AD109 (review; one author is an Apnimed employee)

“While anatomical vulnerability contributes to airway instability, a key determinant of OSA pathophysiology is the sleep-related reduction in upper airway neuromuscular activity that occurs at the wake–sleep transition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Nonanatomical causes contribute to OSA in approximately 70% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This endogenous noradrenergic excitation at the HMN is present in wakefulness, reduced in non-REM (NREM) sleep, and further reduced in REM sleep.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Upper airway dilator muscle activity decreases during sleep due to withdrawal of excitatory drive, including noradrenergic input, in rapid eye movement (REM) and non-REM (NREM) sleep, and recruitment of inhibitory muscarinic–GIRK (G-protein–coupled inwardly rectifying potassium) mechanisms in REM sleep at upper airway motor nuclei.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“AD109 combines norepinephrine reuptake inhibition (atomoxetine) to restore excitatory drive and antimuscarinic activity (aroxybutynin) to reduce inhibition, thereby stabilizing upper airway muscle tone and improving airway patency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“R.L.H.’s laboratory received an unrestricted grant in September 2024 from Apnimed, Inc. to support future research in obstructive sleep apnea (OSA) pharmacotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“L.T.-M. is an Apnimed employee and is co-inventor of intellectual property for pharmacological therapy of OSA via the Brigham and Women’s Hospital.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Diagnosis
Diagnostic testing: AASM 2017 guideline recommendations on polysomnography and home sleep apnea testing

“Diagnostic testing for OSA should be performed in conjunction with a comprehensive sleep evaluation and adequate follow-up. Polysomnography is the standard diagnostic test for the diagnosis of OSA in adult patients in whom there is a concern for OSA based on a comprehensive sleep evaluation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend that clinical tools, questionnaires and prediction algorithms not be used to diagnose OSA in adults, in the absence of polysomnography or home sleep apnea testing. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend that polysomnography, or home sleep apnea testing with a technically adequate device, be used for the diagnosis of OSA in uncomplicated adult patients presenting with signs and symptoms that indicate an increased risk of moderate to severe OSA. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend that if a single home sleep apnea test is negative, inconclusive, or technically inadequate, polysomnography be performed for the diagnosis of OSA. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We recommend that polysomnography, rather than home sleep apnea testing, be used for the diagnosis of OSA in patients with significant cardiorespiratory disease, potential respiratory muscle weakness due to neuromuscular condition, awake hypoventilation or suspicion of sleep related hypoventilation, chronic opioid medication use, history of stroke or severe insomnia. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We suggest that, if clinically appropriate, a split-night diagnostic protocol, rather than a full-night diagnostic protocol for polysomnography be used for the diagnosis of OSA. (WEAK)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We suggest that when the initial polysomnogram is negative and clinical suspicion for OSA remains, a second polysomnogram be considered for the diagnosis of OSA. (WEAK)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Home sleep apnea testing: candidate criteria, device requirements, and respiratory event index

“An increased risk of moderate to severe OSA is indicated by the presence of excessive daytime sleepiness and at least two of the following three criteria: habitual loud snoring, witnessed apnea or gasping or choking, or diagnosed hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A technically adequate HSAT device incorporates a minimum of the following sensors: nasal pressure, chest and abdominal respiratory inductance plethysmography, and oximetry; or else PAT with oximetry and actigraphy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A technically adequate diagnostic test includes a minimum of 4 hours of technically adequate oximetry and flow data, obtained during a recording attempt that encompasses the habitual sleep period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Measurement error is inevitable in HSAT, compared against PSG, as standard sleep staging channels are not typically monitored in HSAT (e.g., EEG, EOG and EMG monitoring are not typically performed), which results in use of the recording time rather than sleep time to define the denominator of the respiratory event index (REI; the term used to represent the frequency of apneas and hypopneas derived from HSAT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“HSAT devices that use conventional sensors are unable to detect hypopneas only associated with cortical arousals, which are included in the recommended AHI scoring rule in the AASM Scoring Manual.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Scoring rules: AASM 2012 recommended hypopnea rule with 3% desaturation or arousal, and 4% rule for reimbursement

“Score a respiratory event as a hypopnea if all of the following are met:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The peak signal excursions drop by ≥ 30% of pre-event baseline using nasal pressure (diagnostic study), PAP device flow (titration study), or an alternative hypopnea sensor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The duration of the ≥ 30% drop in signal excursions is ≥ 10 seconds.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There is ≥ 3% oxygen desaturation from pre-event baseline or the event is associated with an arousal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Note: If necessary, the number of hypopneas using a definition requiring ≥ 30% drop in flow for ≥ 10 seconds that is associated with ≥ 4% desaturation may additionally be reported to qualify a patient for PAP reimbursement (e.g., Medicaid or Medicare patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For Medicaid and Medicare patients the use of a hypopnea definition based on a 30% drop in flow and 4% or greater desaturation will need to be used to ensure reimbursement until reimbursement policies are changed to reflect the new hypopnea definition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Medicare coverage thresholds: CPAP national coverage determination, AHI or RDI with 4% desaturation hypopnea rule

“Apnea is defined as a cessation of airflow for at least 10 seconds. Hypopnea is defined as an abnormal respiratory event lasting at least 10 seconds with at least a 30% reduction in thoracoabdominal movement or airflow as compared to baseline, and with at least a 4% oxygen desaturation.” (opens the source at this quote in a new tab)

“The AHI and/or RDI may be measured by polysomnography (PSG) in a facility-based sleep study laboratory, or by a Type II home sleep test (HST) monitor, a Type III HST monitor, or a Type IV HST monitor measuring at least 3 channels.” (opens the source at this quote in a new tab)

“An initial 12-week period of CPAP is covered in adult patients with OSA if either of the following criterion using the AHI or RDI are met:” (opens the source at this quote in a new tab)

“AHI or RDI greater than or equal to 15 events per hour, or” (opens the source at this quote in a new tab)

“AHI or RDI greater than or equal to 5 events and less than or equal to 14 events per hour with documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease, or history of stroke.” (opens the source at this quote in a new tab)

“If the AHI or RDI is calculated based on less than 2 hours of continuous recorded sleep, the total number of recorded events to calculate the AHI or RDI during sleep testing must be at a minimum the number of events that would have been required in a 2-hour period.” (opens the source at this quote in a new tab)

Clinical presentation - signs and symptoms
Long-term morbidity
Burden of Obstructive sleep apnea
Humanistic burden and health-related quality of life
Health-related quality of life, utility, and work productivity with and without excessive sleepiness in the US National Health and Wellness Survey
Economic burden and healthcare resource utilization
Economic impact of Obstructive sleep apnea on families

Not applicable.

Economic impact of diagnostic testing

Approaches to treatment

Current treatment options and standard of care
Positive airway pressure therapy
AASM guideline: PAP for excessive sleepiness (strong), impaired sleep-related quality of life (conditional), and comorbid hypertension (conditional)
SAVE: CPAP and cardiovascular events in OSA with established cardiovascular disease, OSA defined by a 4% oxygen desaturation index of at least 12

“The diagnosis of moderate-to-severe obstructive sleep apnea, which was defined as an oxygen desaturation index (the number of times per hour during the oximetry recording that the blood oxygen saturation level drops by ≥4 percentage points from baseline) of at least 12, was established with the use of a home sleep-study screening device (ApneaLink, ResMed) and was confirmed by review of the data at a central core sleep laboratory.” (opens the source at this quote in a new tab)

“In the CPAP group, the mean duration of adherence to CPAP therapy was 3.3 hours per night, and the mean apnea–hypopnea index (the number of apnea or hypopnea events per hour of recording) decreased from 29.0 events per hour at baseline to 3.7 events per hour during follow-up.” (opens the source at this quote in a new tab)

“After a mean follow-up of 3.7 years, a primary end-point event had occurred in 229 participants in the CPAP group (17.0%) and in 207 participants in the usual-care group (15.4%) (hazard ratio with CPAP, 1.10; 95% confidence interval, 0.91 to 1.32; P=0.34).” (opens the source at this quote in a new tab)

“CPAP significantly reduced snoring and daytime sleepiness and improved health-related quality of life and mood.” (opens the source at this quote in a new tab)

“Therapy with CPAP plus usual care, as compared with usual care alone, did not prevent cardiovascular events in patients with moderate-to-severe obstructive sleep apnea and established cardiovascular disease.” (opens the source at this quote in a new tab)

Adherence: 90-day adherence by the Medicare definition in a device manufacturer’s cloud database

“We assessed de-identified data from a large cloud database of positive airway pressure (PAP) users to examine adherence to therapy during the period 1-Oct-2014 to 31-Oct-2017.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All Air10 platform PAP devices (ResMed Inc., San Diego, USA) have an on-board mobile communications chip which connects to the secure cloud infrastructure automatically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“ResMed Corp, USA funded the study and their employees (JA, AB, CMN) contributed to the design and conduct of the study, analysis, and interpretation of the data and preparation of the manuscript for publication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The primary outcome was adherence, which was defined using the US Center for Medicare and Medicaid Services (CMS) definition (≥4 hours’ PAP use on 70% of nights in a consecutive 30-day period in the first 90 days of therapy).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The observed 90-day PAP adherence rate using the CMS definition was 75%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Prior studies suggest that up to 24% of patients may not fulfill their PAP prescription [14] and a proportion of patients may not even turn on their PAP machine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Oral appliance therapy
Weight management and incretin-based pharmacotherapy
Tirzepatide label: week 52 AHI results in Studies 5 and 6, modified intent-to-treat population, hypopneas scored with 4% oxygen desaturation
MeasureStudy 5 placebo (N = 120)Study 5 ZEPBOUND MTD (N = 114)Study 5 difference from placebo (95% CI)Study 6 placebo (N = 114)Study 6 ZEPBOUND MTD (N = 119)Study 6 difference from placebo (95% CI)
AHI change from baseline (events/hr)“-5.3”“-25.3”“-20 (-25.8, -14.2)”“-5.5”“-29.3”“-23.8 (-29.6, -17.9)”
Percent change in AHI from baseline“-3”“-50.7”“-47.7 (-65.8, -29.6)”“-2.5”“-58.7”“-56.2 (-73.7, -38.7)”
Percent of participants with ≥50% reduction in AHI“19”“61.2”“42.8 (30.8, 54.8)”“23.3”“72.4”“48.6 (36.6, 60.7)”
Percent with AHI <5 or AHI 5-14 and ESS ≤10“15.9”“42.2”“28.7 (18.3, 39.2)”“14.3”“50.2”“33.2 (22.1, 44.3)”
SURMOUNT-OSA: AHI change at week 52, treatment-regimen estimand, hypopneas scored with 4% oxygen desaturation
Positional therapy
ERS guideline: vibratory positional therapy or CPAP in mild or moderate position-dependent OSA (conditional recommendation, very low certainty of evidence), hypopnea scoring rule not stated
Hypoglossal nerve stimulation
Upper airway and maxillomandibular surgery
Evidence base, benefits, and harms of upper airway surgery as rescue therapy
Wakefulness-promoting agents for residual sleepiness
Limitations of current therapies
Summary
  • PAP nonadherence, by definition: with adherence defined as more than 4 hours of nightly use, 46% to 83% of people with OSA have been reported to be nonadherent (Weaver and Grunstein 2008). Relative to a 7-hour night, the overall CPAP non-adherence rate across 20 years of studies was 34.1%, with no significant improvement over that period (Rotenberg et al. 2016). By the CMS definition (at least 4 hours of use on 70% of nights in a consecutive 30-day period within the first 90 days), the observed 90-day adherence rate was 75% (Cistulli et al. 2019), which also cites prior studies in which up to 24% of patients may not fulfill their PAP prescription. The VA/DoD 2025 guideline states that as many as half of patients prescribed PAP have been unable to adopt it long-term. Mean adherence in the CPAP groups of two cardiovascular outcome trials was 3.3 hours per night (McEvoy et al. 2016) and 2.78 hours per night (Sánchez-de-la-Torre et al. 2020).
  • PAP termination and persistence: in claims data, with termination defined as cessation of CPAP reimbursements, termination rates among 480,000 people were 23.1%, 37.1%, and 47.7% after 1, 2, and 3 years (Pépin et al. 2021); a second analysis of 174,270 individuals reported a 1-year termination rate of 22.3% (Bailly et al. 2024). Under telemonitoring (95.7% of 84,550 people), PAP persistence was 83.5% at 1 year, 68.4% at 3 years, and 60.5% at 5 years, and issues with PAP treatment accounted for 54.9% of documented reasons for stopping (Baillieul et al. 2026).
  • Cardiovascular outcomes: CPAP did not reduce cardiovascular events in randomized trials. In one trial (McEvoy et al. 2016), a primary end-point event occurred in 17.0% of the CPAP group and 15.4% of the usual-care group after a mean 3.7 years (hazard ratio 1.10; 95% CI 0.91 to 1.32). Cardiovascular events occurred in 16% vs 17% in a second trial (Sánchez-de-la-Torre et al. 2020; hazard ratio 0.89; 95% CI 0.68 to 1.17), and the primary endpoint in 18.1% vs 22.1% in a third (Peker et al. 2016; hazard ratio 0.80; 95% CI 0.46 to 1.41). A meta-analysis of 10 randomized trials (7266 participants) found a relative risk of 0.77 (95% CI 0.53 to 1.13) for a composite of acute coronary syndrome, stroke, or vascular death. An individual participant data meta-analysis (4186 participants) found a hazard ratio of 1.01 (95% CI 0.87 to 1.17) for the first major adverse cardiac or cerebrovascular event, and 0.69 (95% CI 0.52 to 0.92) with good adherence in an on-treatment analysis. The AASM guideline finds insufficient and inconclusive evidence to recommend or withhold PAP in non-sleepy adults to reduce cardiovascular events or mortality.
  • Oral appliances: in pooled trials (hypopnea scoring rule not stated), the mean AHI reduction was 6.24 events/h greater with CPAP than with oral appliances, and the odds of reaching the target AHI in moderate to severe OSA were greater with CPAP; no randomized trial has compared objective oral appliance adherence with CPAP (AASM and AADSM guideline). The ERS guideline suggests CPAP over mandibular advancement devices (conditional recommendation, very low quality of evidence) and regards the two as equal in mild to moderate OSA.
  • Positional therapy: guideline recommendations apply to positional OSA (VA/DoD, weak for) and to mild or moderate position-dependent OSA with a nonsupine AHI below 15 events/h (ERS). In a review of 8 studies (323 participants; hypopnea scoring rule not stated), CPAP reduced the AHI by 6.4 events per hour more than positional therapy (2 studies), all studies were of short duration, and long-term effects could not be assessed. The VA/DoD guideline states that positional therapy was not associated with improved functional outcomes or quality of life, with very low confidence in the evidence.
  • Hypoglossal nerve stimulation: the FDA device criteria summarized by the VA/DoD guideline include moderate to severe OSA with an AHI of 15 to 100 events per hour and failure of or intolerance to PAP. The ERS guideline suggests against its use as first-line treatment and suggests it as salvage treatment for patients with an AHI below 50 events/h and a BMI below 32 kg/m2; its trials included about 10% of screened patients. In one randomized trial cited by the VA/DoD guideline, 72.5% of 138 participants experienced a total of 164 procedure- or study-related adverse events. Apnimed cites invasiveness, cost, and BMI and airway collapse pattern exclusions, and states that approximately 100,000 patients had received the therapy as of March 2025.
  • Tirzepatide: its OSA indication is limited to moderate to severe OSA in adults with obesity, with a reduced-calorie diet and increased physical activity; its OSA trials enrolled adults with an AHI of at least 15 and a BMI of at least 30 kg/m2. The AASM fact sheet states that there is no head-to-head evidence comparing it with other OSA treatments.
  • Wake-promoting agents: the solriamfetol and armodafinil labels indicate them to improve wakefulness in OSA and state that neither treats the underlying airway obstruction.
Place in treatment, anticipated use, and care setting
Summary
  • Guideline sequencing: the VA/DoD 2025 algorithm prescribes PAP as first-line therapy for severe OSA (AHI above 30 events per hour) and PAP or a mandibular advancement device for an AHI of 5 to below 30, and refers patients who do not adopt or use PAP or a mandibular advancement device to a sleep medicine specialist. The ACP recommends CPAP as initial therapy (strong recommendation, moderate-quality evidence) and mandibular advancement devices as an alternative (weak recommendation, low-quality evidence). The AASM and AADSM recommend that sleep physicians consider oral appliances for adults intolerant of CPAP therapy or preferring alternate therapy. After PAP is unsuccessful or not accepted, guidelines suggest referral for hypoglossal nerve stimulation evaluation when the AHI is 15 or more per hour (VA/DoD) and recommend discussing referral to a sleep surgeon when the BMI is below 40 kg/m2 or to a bariatric surgeon when the BMI is 35 kg/m2 or more (AASM). Wake-promoting agents are suggested for residual excessive daytime sleepiness in patients optimally treated with sufficient therapy use (VA/DoD).
  • VA/DoD 2025 Recommendation 24 suggests against atomoxetine or a combination of atomoxetine and oxybutynin for OSA (“Weak against”). It rests on 2 randomized trials with mixed results, low confidence in the evidence, and known harms (atomoxetine may increase blood pressure; oxybutynin's anticholinergic effects can increase the risk of falls and cause cognitive impairment). The guideline notes that aroxybutynin is not approved by the FDA. Its evidence review ended on March 31, 2024, and it states that randomized trials of these agents as salvage or adjunctive therapy are needed; Apnimed states that both AD109 phase 3 trials, SynAIRgy and LunAIRo, were completed in 2025.
  • AD109 phase 3 population: SynAIRgy and LunAIRo enrolled adults with mild to severe OSA who were intolerant of or refused PAP. PAP failure was defined as no PAP use for at least 3 months before randomization or return or removal of the device, and PAP refusal as refusal of PAP after a positive sleep study or refusal of a recommended sleep study due to unwillingness to consider PAP. In the SynAIRgy intent-to-treat set of 615 participants, 411 (66.8%) had PAP intolerance and 205 (33.3%) PAP refusal.
  • Apnimed's stated positioning: the initial launch would focus on the approximately 10.5 million people in the United States diagnosed with OSA but untreated (from a 2025 National Sleep Foundation survey), then on patients using another treatment whose OSA is not fully resolved (as a complement to PAP or GLP-1 therapies), with first-line use as the long-term target. The company presentation describes the target patient as intolerant to PAP (refused or failed), diagnosed within the past 2 years, and without insomnia or active cardiovascular disease. Apnimed plans 125 to 150 field representatives covering 15,000 to 20,000 sleep specialists and high-volume primary care practices. Company-cited surveys report that 84% of surveyed healthcare providers familiar with Oxnimbi intend to prescribe it (Wells Fargo, August 2025) and that approximately 80% of 1,500 surveyed patients reported likelihood of asking their healthcare provider to try a nightly pill proven to improve OSA (SHINE Survey).
  • An editorial on SynAIRgy describes AD109 as a likely addition to a multimodal treatment framework, particularly for patients unable or unwilling to use PAP.
VA/DoD 2025 Recommendation 24 against atomoxetine or atomoxetine plus oxybutynin

“For treatment of obstructive sleep apnea, we suggest against atomoxetine or a combination of atomoxetine and oxybutynin. (Weak against | Reviewed, New-added)” (opens the source at this quote in a new tab)

“Evidence from 2 RCTs (203,204) provided mixed results on whether atomoxetine or the combination of atomoxetine and oxybutynin improve critical outcomes of obstructive sleep apnea (OSA) such as reductions in apnea hypopnea index (AHI), improvements in daytime functioning, or sleep-related quality of life (QoL).” (opens the source at this quote in a new tab)

“The combination of atomoxetine and aroxybutynin showed a reduction in AHI, daytime fatigue, and respiratory arousal. Aroxybutynin, the R-enantiomer of oxybutynin, is not approved by the FDA and not commercially available.” (opens the source at this quote in a new tab)

“Confidence in the quality of overall evidence was rated as low due to small sample sizes and the risk for imprecision. A weak against recommendation for atomoxetine and the combination of atomoxetine and oxybutynin was made because of known harms from these medications, inconclusive evidence that they are effective in OSA, and the low quality of evidence.” (opens the source at this quote in a new tab)

“Specifically, atomoxetine may increase blood pressure and exacerbate cardiovascular disorders and oxybutynin’s anticholinergic effects can increase risk for falls and cause cognitive impairment.” (opens the source at this quote in a new tab)

Heterogeneity of treatment effect
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy